Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI.

ABSTRACT:

Background

AKI commonly occurs in patients with coronavirus disease 2019 (COVID-19). Its pathogenesis is poorly understood. The urokinase receptor system is a key regulator of the intersection between inflammation, immunity, and coagulation, and soluble urokinase plasminogen activator receptor (suPAR) has been identified as an immunologic risk factor for AKI. Whether suPAR is associated with COVID-19-related AKI is unknown.

Methods

In a multinational observational study of adult patients hospitalized for COVID-19, we measured suPAR levels in plasma samples from 352 adult patients that had been collected within 48 hours of admission. We examined the association between suPAR levels and incident in-hospital AKI.

Results

Of the 352 patients (57.4% were male, 13.9% were b

SUBMITTER: Azam TU 

PROVIDER: S-EPMC7608953 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature